Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomized study of Velcade/melphalan/prednisone versus melphalan/prednisone in subjects with previously untreated multiple myeloma

Next Previous
X
Search
Trial Profile

An open-label, randomized study of Velcade/melphalan/prednisone versus melphalan/prednisone in subjects with previously untreated multiple myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms VISTA
  • Sponsors Janssen-Cilag; Millennium

    • Most Recent Events

    • 10 Dec 2013 Results for the effects of cumulative bortezomib dose on outcomes presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 09 Dec 2013 Additional results were presented at the 55th Annual Meeting and Exposition of the American Society of Hematology (ASH-2013).
    • 12 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Janssen-Cilag media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top